Lazolvan, syrup 30 mg/5 ml 100 ml

Ambroxol is the active ingredient of the drug Lazolvan. It has secretomotor, secretolytic and expectorant action. It stimulates serous cells of glands of bronchial mucosa. Ambroxol increases the production of pulmonary surfactant, stimulates ciliary activity and normalizes the disturbed ratio of serous and mucous components of sputum. By activating hydrolyzing enzymes and enhancing the release of lysosomes from the Clara cells, it reduces the viscosity of sputum. Ambroxol increases the flow and transport of mucus (mucociliary clearance). Increasing mucociliary clearance improves sputum discharge and makes it easier to cough.

Pharmacokinetics

Ambroxol is characterized by rapid and almost complete absorption with linear dose-dependence in the therapeutic concentration range. Cmax with oral administration is reached after 1-2.5 hours. Vd after oral administration is 552 l. In the therapeutic range of concentrations binding to plasma proteins is approximately 90%.

The transfer of ambroxol from the blood to the tissues when administered orally is rapid. The highest concentrations of the active component of the drug are observed in the lungs. Approximately 30% of the orally administered dose undergoes primary metabolism. Studies on human liver microsomes have shown that CYP3A4 is the predominant isoform responsible for metabolizing ambroxol to dibromanthranilic acid. The remainder of ambroxol is metabolized in the liver primarily by glucuronidation and by partial cleavage to dibromanthranilic acid (approximately 10% of the administered dose), as well as a small number of additional metabolites. The terminal T1/2 of ambroxol is 10 h. Total clearance is within 660 ml/min, renal clearance accounts for approximately 8% of total clearance.

There has been no clinically significant effect of age and sex on the pharmacokinetics of ambroxol, so there is no reason to make any dosage change based on these characteristics.

In patients with hepatic impairment, ambroxol excretion is delayed, resulting in a 1.3-2-fold increase in plasma ambroxol levels. Due to the wide therapeutic range of ambroxol, no dose reduction is required.

Indications

Active ingredient

Composition

Active ingredients:

Ambroxol hydrochloride 30 mg.

Auxiliary substances:

benzoic acid – 8.5 mg,

hyetellose (hydroxyethylcellulose) – 10 mg,

potassium acesulfame – 5 mg,

sorbitol liquid (noncrystallizing) – 1750 mg,

Glycerol 85% – 750 mg,

Strawberry and creamy flavoring PHL-132200 – 12 mg,

How to take, the dosage

The drug is administered orally, regardless of meals.

Lazolvan® Syrup 15 mg/5 ml is indicated:

Lazolvan® Syrup 30 mg/5 ml is indicated:

If symptoms persist within 4-5 days of starting the drug, consult a physician.

Interaction

Should not be combined with cough suppressants making it difficult to expectorate sputum.

The oral and inhaled solution contains benzalkonium chloride. In patients with overactive airways, this preservative may cause bronchial spasm during inhalation.

Special Instructions

Should not be combined with cough suppressants making it difficult to expectorate sputum.

The oral and inhaled solution contains benzalkonium chloride. In patients with overactive airways, this preservative may cause bronchial spasm during inhalation.

Contraindications

With caution should be prescribed: in the second and third trimesters of pregnancy, and in patients with renal and/or hepatic impairment.

Side effects

Allergic reactions: skin rash, urticaria, angioneurotic edema, in some cases – allergic contact dermatitis. Extremely rare cases of acute severe reactions of anaphylactic type (anaphylactic shock) have been reported.

In long-term use in high doses – heartburn, gastralgia, nausea, vomiting.

Overdose

Symptoms: nausea, vomiting, diarrhea, dyspepsia, gastralgia are possible.

Treatment: induction of vomiting, gastric lavage during the first 1-2 hours after taking the drug; intake of fat-containing products, symptomatic therapy.

Similarities